Abstract | OBJECTIVE: To review the pharmacology, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy of insulin glargine. DATA SOURCES: Primary and review articles regarding insulin glargine were identified by MEDLINE search (1966-July 2001); abstracts were identified through Institute for Scientific Information Web of Science (1995-July 2001) and the American Diabetes Association. Additional information was obtained from the insulin glargine product information. STUDY SELECTION AND DATA EXTRACTION: All of the articles and meeting abstracts identified from the data sources were evaluated, and all information deemed relevant was included in this review. Priority was placed on data from the primary medical literature. DATA SYNTHESIS: CONCLUSIONS:
|
Authors | Terri L Levien, Danial E Baker, John R White Jr, R Keith Campbell |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 36
Issue 6
Pg. 1019-27
(Jun 2002)
ISSN: 1060-0280 [Print] United States |
PMID | 12022906
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Chemical References |
- Insulin
- Insulin, Long-Acting
- Insulin Glargine
|
Topics |
- Amino Acid Sequence
- Clinical Trials as Topic
- Diabetes Mellitus
(classification, drug therapy)
- Drug Administration Schedule
- Drug Interactions
- Economics, Pharmaceutical
- Humans
- Insulin
(adverse effects, analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use)
- Insulin Glargine
- Insulin, Long-Acting
|